- 註冊時間
- 2023-5-6
- 精華
- 在線時間
- 小時
- 米币
-
- 最後登錄
- 1970-1-1
|
發表於 2025-1-4 03:09:28
|
顯示全部樓層
RESPONSE OF MICROPENIS TO TOPICAL TESTOSTERONE AND6 o: x+ S" y, A3 v$ B
GONADOTROPIN
6 r% l, d3 F& b% P" {RICHARD C. KLUGO* AND JOSEPH C. CERNY. C& k) c' ]+ ~
From the Division of Urology, Henry Ford Hospital, Detroit, Michigan, i7 Z) @1 ^& d1 L
ABSTRACT6 K/ Y ^: @" u) E4 C! t7 t
Five patients were treated with gonadotropin and topical testosterone for micropenis associated
2 |+ ^# u. K/ S+ r, o( V$ Swith hypothalamic hypogonadotropic hypogonadism. All patients received 1,000 units of gonado-
" _* k) H1 ]8 w; o! A: Gtropin weekly for 3 weeks, with a 6-week interval followed by 10 per cent topical testosterone8 L6 {; P+ y8 u* v+ n- n: }0 o
cream twice daily for 3 weeks. Serum testosterone levels were measured and remained equivalent& V) N; t" P* ~# O, d2 V; n
for both modes of therapy. Average penile growth response with gonadotropin was 14.3 per cent
( I; a2 T, H( Kincrease in length and 5.0 per cent increase of girth. Topical testosterone produced an average1 ~1 e! u6 R3 `' r' S
increase of 60 per cent in penile length and 52. 9 per cent in girth. The greatest growth response$ E5 S7 d. i: E i6 f1 H2 q3 H" C
occurred in prepuberal male subjects with a minimal response in postpuberal male subjects. This0 Z4 |; T6 L3 I& f
study suggests that 10 per cent topical testosterone cream twice daily will produce effective penile
# y% t* g1 w% N% igrowth. The response appears to be greater in younger children, which is consistent with previ-; p6 V: O* k2 N
ously published studies of age-related 5 reductase activity.4 b" q4 M: g, F) P3 H8 O
Children with microphallus regardless of its etiology will) Q4 \$ V' b* J4 _
require augmentation or consideration for alteration of exter-
6 K+ T2 H0 V; n6 b( Qnal genitalia. In many instances urethroplasty for hypo-
: j/ H; Q4 [( I* Qspadias is easier with previous stimulation of phallic growth.
?- T4 q/ S* k7 S6 TThe use of testosterone administered parenterally or topically4 v5 V7 u2 [& X/ l a. g; @
has produced effective phallic growth. 1- 3 The mechanism of
6 r" @# U% G$ A) j) E% ~response has been considered as local or systemic. With this4 V- U; z5 ^! ^2 Y* \' p
in mind we studied 5 children with microphallus for response
% t& z1 d$ J6 A2 x: E% c5 _. Oto gonadotropin and to topical testosterone independently.9 C3 B2 Y5 W$ c) Y2 E2 G
MATERIALS AND METHODS
) k* \9 ?. q, Q6 I t1 TFive 46 XY male subjects between 3 and 17 years old were0 b; t+ L% |/ y; g
evaluated for serum testosterone levels and hypothalamic
4 k9 ]3 j- Y7 k/ t! ffunction. Of these 5 boys 2 were considered to have Kallmann's
' B/ J2 e! v: X! qsyndrome, 1 Prader-Willi syndrome and 2 idiopathic hypotha-
: M3 y2 j% M0 q% S, s9 f/ f& d0 Mlamic deficiency. After evaluation of response to luteinizing" o% ?! W) @* H" R7 g7 U
hormone-releasing hormone these patients were treated with' @9 ]- K4 `8 d* c+ w8 A! M/ c
1,000 units of gonadotropin weekly for 3 weeks. Six weeks
: `5 P8 f8 H7 s- D+ wafter completion of gonadotropin therapy 10 per cent topical
6 K/ k7 o/ j' r8 z& r% M2 vtestosterone was applied to the phallus twice daily for 3 weeks.7 A. D% b& @$ N# ^! m. i8 s( H+ ~
Serum testosterone, luteinizing hormone and follicle-stimulat-
. t Y4 u7 V6 G- ?$ u8 r( q6 @* eing hormone were monitored before, during and after comple-8 I X: ?, g2 w
tion of each phase of therapy. Penile stretch length was
' s& Y, o$ t9 C! E k8 g7 I" hobtained by measuring from the symphysis pubis to the tip of. Y8 y* d; U% A2 S/ [& f/ K
the glans. Penile circumferential (girth) measurements were
. F8 r/ s( Y! W3 M# {# [2 Wobtained using an orthopedic digital measuring device (see/ C# @1 v! N( \$ I
figure).% \2 X+ M* e# o2 L/ P1 G$ R+ K. ?. F
RESULTS
$ ^$ ?$ o6 l; D; X' k$ c1 w8 @Serum testosterone increased moderately to levels between% \* a# i% G/ D2 h9 e9 `# i
50 and 86 ng./dl. with gonadotropin stimulation. Serum testos-
3 u! J5 J& B3 rterone levels with topical testosterone remained near pre-
% L# a1 j4 @# ztreatment levels (35 ng./dl.) or were elevated to similar levels2 g ]9 ]& ?4 g. K2 O( g) Z* O
developed after gonadotropin therapy (96 ng./dl.). Higher" s& r$ M0 N' N* b
serum levels were noted in older patients (12 and 17 years old),$ d3 x. M7 E; s8 d4 Q
while lower levels persisted in younger patients (4, 8, and 103 Z* L" w( T+ G$ l; ^8 y& K h
years old) (see table). Despite absence of profound alterations3 n( e- N, Z k8 f s
of serum testosterone the topical therapy provided a greater5 r: n# h# q& U/ `" Q
Accepted for publication July 1, 1977. ·$ U* u. v$ w. m g% u
Read at annual meeting of American Urological Association,7 `2 ?- G1 G) G3 j9 v. z* q3 B
Chicago, Illinois, April 24-28, 1977.
; X' }6 l, [) L6 q' j* Requests for reprints: Division of Urology, Henry Ford Hospital,
. Z/ A/ ?# O7 c6 R/ u2799 W. Grand Blvd., Detroit, Michigan 48202.' B' t6 O0 a: `0 t/ ?: M* }
improvement in phallic growth compared to gonadotropin.
7 t: \/ a0 @' o/ K. GAverage phallic growth with gonadotropin was 14.3 per cent" T2 }$ [5 V7 [6 c Q2 X- M
increase in length and 5.0 per cent increase of girth. Topical. S# z/ O" r. V" x/ M- R
testosterone produced a 60.0 per cent increase of phallic length
5 {& q, x0 G) w+ s& E. `" p8 |and 52.9 per cent increase of girth (circumference). The' W# B4 A7 ~8 j- a1 I* t, h
response to topical testosterone was greatest in children be-/ ~/ G2 P3 n h8 Q; B7 ]
tween 4 and 8 years old, with a gradual decrease to age 17
! x; Z' u1 K# wyears (see table).( J* p! H) [. a- |9 C# x
DISCUSSION
/ ^3 y. r7 E/ X0 P- k0 GTopical testosterone has been used effectively by other* x% U# F' J2 A* H: s( n+ G/ Z# t
clinicians but its mode of action remains controversial. Im-0 X3 y l+ P. p1 g. N* y. z$ J3 a
mergut and associates reported an excellent growth response
! G- i9 U' t( _2 j$ w6 o9 Oto topical testosterone with low levels of serum testosterone,; B5 `! W* e9 u, P* K$ P7 q" L+ L
suggesting a local effect.1 Others have obtained growth re-
}7 h$ l6 R0 T$ }7 ssponse with high. levels of serum testosterone after topical3 N( g8 s2 Y) v) B& \% @
administration, suggesting a systemic response. 3 The use of
& y; g$ Q$ H. `/ z! cgonadotropin to obtain levels of serum testosterone compara-& e" {: i5 C8 X4 T
ble to levels obtained with topical testosterone would seem to
5 G8 E2 u5 k# ]2 f. b- }. aprovide a means to compare the relative effectiveness of
+ W+ M$ p- X7 @& ]4 ^2 Rtopical testosterone to systemic testosterone effect. It cer-
$ `3 p8 t9 q' ]0 \. Otainly has been established that gonadotropin as well as par-6 ^3 m- g7 O$ j+ p
enteral testosterone administration will produce genital
4 D% m2 E6 C# Mgrowth. Our report shows that the growth of the phallus was
B5 g) { A- t4 T0 @0 {- y0 I, C0 Tsignificantly greater with topical applications than with go-
4 e! v; \4 V, [$ Nnadotropin, particularly in children less than 10 years old.
' S, H4 Q' [# t5 ? _5 zThe levels of serum testosterone remained similar or lower
' N- Z: _- i3 z E! [than with gonadotropin during therapy, suggesting that topi-
' I# k' C) E/ J/ x/ Lcal application produces genital growth by its local effect as
1 p) a8 @) f" g' Y: O. Dwell as its systemic effect.4 I) R) q( C& e8 ~& H) ]
Review of our patients and their growth response related to
4 w2 B9 m4 v+ b/ R3 hage shows a greater growth response at an earlier age. This is
) y. L) T* y* Vconsistent with the findings of Wilson and Walker, who- b4 L4 T8 X C4 k; `+ a' x
reported an increased conversion of testosterone to dihydrotes-
% n' z J; c- g; Ltosterone in the foreskin of neonates and infants.4 This activ-
1 o. }7 w( L) b8 {. s" ?: Mity gradually decreases with age until puberty when it ap-7 v6 `8 |5 e! r
proaches the same level of activity as peripheral skin. It may4 J$ Y& N! i( W0 l3 G& B9 L1 ~
well be that absorption of testosterone is less when applied at8 F8 \7 k) B% k! F- i. F# C$ ?
an earlier age as suggested by lower serum levels in children; ]5 l3 r O6 w
less than 10 years old. This fact may be explained by the5 L9 ?9 F. W; i4 G* `/ y, L) `) B
greater ability of phallic skin to convert testosterone to dihy-) Z6 o1 P+ @6 M' P
drotestosterone at this age. Conversely, serum levels in older( K5 O+ ]8 `9 K$ d' Z# M0 I% }
patients were higher, possibly because of decreased local2 o* R2 l/ n v; n Y5 e+ r6 \
667
q& V- y j0 Y( I6 F" T/ @668 KLUGO AND CERNY( i' S5 @9 M: J
Pt. Age8 n4 ?( ~' E; j1 @2 Q, _( D5 R
(yrs.). d4 J8 S* [* J1 `. \: E
Serum Testosterone Phallus (cm.) Change Length' O& I8 T9 S& e' S
(ng./dl.) Girth x Length (%)
1 N0 Q Z9 E7 R D) B& K4" V2 t1 z1 Z. T; \6 q& n
85 R' {5 v4 [. j& G& ~1 W" C+ f& z6 F
107 i! u5 i1 [& N5 M w; ^0 ~! k
12
5 O5 _( Q+ `1 K6 C+ i' C17
6 a7 o! {7 l( z: e! n- a& ?Gonadotropin
0 K" q5 B f; \% e7 ]71.6 2.0 X 3 16.6
6 T, `5 Z( E8 \* L, H: l50.4 4.0 X 5.0 20.0, P4 A ]2 ?0 I* h/ f" b
22.0 4.5 X 4.0 25.0) a2 C( p' X; Z) i' o4 ^
84.6 4.0 X 4.5 11.10 H+ o' H$ [( K# p. P- C; O: O( @
85.9 4.5 X 5.5 9.0& N2 O7 |4 L/ T. N; ]8 @6 q
Av. 14.3+ ^$ {9 `! ]; l! r0 |
4
% }3 T. D( q7 Y8' V3 L& r9 c8 z& d) C. b2 H H9 q
10
% W- h7 e% {5 H8 c, U12/ x4 n: W3 L' i0 {
17
; n* i7 A! K' CTopical testosterone
: \6 `& F8 D+ Z/ S34.6 4.5 X 6.5 859 N. U6 g8 S1 K* F, [
38.8 6.0 X 8.5 70' L7 L( J+ Q& D# O- \) d
40.0 6.0 X 6.5 62.5, u5 [: ]9 k' O7 n
93.6 6.0 X 7.0 55.56 \- A; q' j& _$ I0 O7 a, O
95.0 6.5 X 7.0 27.2
2 e; m9 s) G) ]9 r1 R+ y6 r: fAv. 60.0: d: F P! ?/ }. T
available testosterone. Again, emphasis should be placed on
) T2 W/ M7 s/ o2 s9 j- Yearly therapy when lower levels of testosterone appear to
/ s) o6 i( Y: m* g# oprovide the best responses. The earlier therapy is instituted% ?5 L, Y7 B2 {) x6 V& \
the more likely there will be an excellent response with low
! g" r: R8 m! ?3 y2 E1 fserum levels. Response occurs throughout adolescence as) c6 {! k2 ] m( h+ S; _
noted in nomograms of phallic growth. 7 The actual response, ^8 q1 l' V+ Y' `. Q# \) f
to a given serum level of testosterone is much greater at birth' M8 U0 d$ M! Q9 y s \+ [' ^
and gradually decreases as boys reach puberty. This is most
1 B# D! y% \+ ^9 x* clikely related to the conversion of testosterone to dihydrotes-+ g% r' m! S0 d7 t$ [
tosterone and correlates well with the studies of testosterone
% g8 @0 X& K( y9 T+ U" N, Hconversion in foreskin at various ages.
5 p4 S$ t6 d, o6 FThe question arises regarding early treatment as to whether: S! m1 D, D" A5 b( b- N( c3 h0 C& o
one might sacrifice ultimate potential growth as with acceler-. E4 {8 u1 F$ z0 C; a! b
ated bone growth. The situation appears quite the reverse0 _( I: E. o* z3 t3 U0 M- |
with phallic response. If the early growth period is not used
5 R, H/ i8 q+ n* r) o, ]* mwhen 5a reductase activity is greatest then potential growth
' [+ Q1 s4 h* K! n7 |may be lost. We have not observed any regression of growth
) ~4 v2 l2 e& R! [( [! G) w& nattained with topical or gonadotropin therapy. It may well/ G9 |; t1 m& {3 T( W
be that some patients will show little or no response to any
9 E3 T* g6 k, x8 i+ V# _2 Lform of therapy. This would suggest a defect in the ability to
$ W7 ^$ l$ G) R Uconvert testosterone to dihydrotestosterone and indicate that' z/ ~6 q; H: }$ E; @$ |% R
phallic and peripheral skin, and subcutaneous tissue should
( J; Y1 t3 v+ M( c6 W: n! Ybe compared for 5a reductase activity.
8 N0 @' k1 B. ^' yA, loop enlarges to measure penile girth in millimeters. B,8 V1 S8 N4 V( w+ ?4 I
example of penile girth computed easily and accurately.5 `9 N* Y& F$ t6 m0 i; S
conversion of testosterone to dihydrotestosterone. It is in this
( h$ \# e, ?) Y. [- C% Y5 oolder group that others have noted high levels of serum
0 ]# o' _ ~1 z- B4 [1 m% r M% Gtestosterone with topical application. It would also appear
9 i! j/ D/ N: qthat phallic response during puberty is related directly to the
% h3 l+ `# T4 N# _0 E+ i, ?serum testosterone level. There also is other evidence of local: U8 g% F" b+ |4 G: O" s8 l) {; B( L
response to testosterone with hair growth and with spermato-" T! a$ E9 y4 N8 Q
genesis. 5• 6
! p0 S1 B7 H* }/ L' d, r! w8 x# W* QAdministration of larger doses of gonadotropin or systemic3 v" Q+ _4 q ]9 |: E2 n+ V
testosterone, as well as topical applications that produce- H a6 y$ A; f+ L- E9 A4 [
higher levels of serum testosterone (150 to 900 ng./dl.), will, u. x+ c( K" O9 s+ x) h l
also produce phallic growth but risks accelerated skeletal
7 I! ~# k, h$ |0 ^4 C3 l1 ?' Smaturation even after stopping treatment. It would appear: L- w( G5 ^4 w" N. [3 S6 `
that this may be avoided by topical applications of testosterone
2 D" C- P h+ B$ e7 C" x6 Y+ Rand monitoring of serum testosterone. Even with this control
* L( G7 Y/ b! y' d8 v& x3 A. ^' Uthe duration of our therapy did not exceed 3 weeks at any
+ z+ n% Z9 P/ i1 u0 }time. It is apparent that the prepuberal male subject may* _. }3 l+ Y' [
suffer accelerated bone growth with testosterone levels near# W/ C+ B1 s6 X7 N0 x
200 ng./dl. When skeletal maturation is complete the level of
6 e. _- V$ o8 m z8 Bserum testosterone can be maintained in the 700 to 1,300 ng./, O5 W: {# v9 ^4 j% t+ @! \
dl. range to stimulate phallic growth and secondary sexual
4 j7 v: H2 q1 }changes. Therefore, after skeletal maturation parenteral tes-) S' L j7 G2 U3 r& V! Z" g8 W& g* @
tosterone may be used to advantage. Before skeletal matura-
/ Y% Z$ d I* W; C. ?tion care must be taken to avoid maintaining levels of serum
; `% c" g' F! `2 M; Ztestosterone more than 100 ng./dl. Low-dose gonadotropin/ I, i! d% p2 Z1 m3 W- B
depends upon intrinsic testicular activity and may require
9 R8 `- h# S7 h8 F# Nprolonged administration for any response.: g2 z$ \ A0 k- G9 f- Z
Alternately, topical testosterone does not depend upon tes-, h B7 J- o. c+ Z' T! L
ticular function and may provide a more constant level of' f# S) w9 R- g1 o; P7 d
REFERENCES+ u2 ?+ V/ F3 s: G& A" A
1. Immergut, M., Boldus, R., Yannone, E., Bunge, R. and Flocks,
0 [1 U7 o+ _3 B ~7 ]- f3 R1 [) cR.: The local application of testosterone cream to the prepub-# @) k7 o9 J/ }, r8 {- B' u
ertal phallus. J. Urol., 105: 905, 1971.6 t' D1 n1 p5 a/ ^9 J/ s
2. Guthrie, R. D., Smith, D. W. and Graham, C. B.: Testosterone
+ {" _4 D: H; l- _/ M+ {5 A, Utreatment for micropenis during early childhood. J. Pediat.,6 j% d( t" s" T. B4 c( L
83: 247, 1973.0 A1 ?2 }( A: O# T! u# _) s0 y
3. Jacobs, S. C., Kaplan, G. W. and Gittes, R. F.: Topical testoster-
/ b. e% h9 r0 ?one therapy for penile growth. Urology, 6: 708, 1975.$ _7 A5 L2 s. E- K
4. Wilson, J. D. and Walker, J. D.: The conversion of testosterone
: \- ]1 U% U/ nto 5 alpha-androstan-17 beta-01-3-one (dihydrotestosterone) by" G0 H1 r7 M. Y, I8 u1 d
skin slices of man. J. Clin. Invest., 48: 371, 1969.
8 u! C# J- y G2 T. o9 M5. Papa, C. M. and Klingman, A. M.: Stimulation of hair growth9 M( J' V- P$ F6 @9 @* Y1 |0 z
by topical application of androgens. J.A.M.A., 191: 521, 1965.5 t3 ?% g4 M* Y6 p
6. Gittes, R. F., Smith, G., Conn, C. A. and Smith, F.: Local
' @: R X3 d1 l) Iandrogenic effect of interstitial cell tumor of the testis. J.
) s+ H( g5 S/ J8 ^Urol., 104: 774, 1970./ D/ U/ j" W: I$ e" P+ m
7. Schonfeld, W. A. and Beebe, G. W.: Normal growth and varia-/ [3 Y4 z7 ^3 A2 ]; g+ w
tion in the male genitalia from birth to maturity. J. Urol., 48: |
|